Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [439]

PrE0807: Neoadjuvant nivolumab without or with lirilumab in cisplatin...

Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA

PrE0807: Neoadjuvant nivolumab without or with lirilumab in cisplatin-ineligible patients with muscle-invasive bladder cancer ( Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA )

CheckMate067 outcomes: Nivolumab plus ipilimumab in advanced melanoma

Dr Jedd Wolchok - Memorial Sloan Kettering Center, New York, USA

CheckMate067 outcomes: Nivolumab plus ipilimumab in advanced melanoma ( Dr Jedd Wolchok - Memorial Sloan Kettering Center, New York, USA )

LEAP-004: Lenvatinib + pembrolizumab for patients with advanced melanoma and...

Dr Ana Arance - Hospital Clínic de Barcelona, Barcelona, Spain

LEAP-004: Lenvatinib + pembrolizumab for patients with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor ( Dr Ana Arance - Hospital Clínic de Barcelona, Barcelona, Spain )

Highlights from ASCO 2021

Dr Bishal Gyawali - Queen's University, Kingston, Canada

Highlights from ASCO 2021 ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

OncoAlert and ecancer ASCO roundup - Day 3

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer ASCO roundup - Day 3 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

RELATIVITY-047: Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first...

Dr Evan Jacob Lipson - Johns Hopkins Sidney Kimmel Comprehensive Cancer Center...

RELATIVITY-047: Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma ( Dr Evan Jacob Lipson - Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA )

Phase III randomised trial comparing tebentafusp with investigator’s choice in...

Dr Jessica Hassel - University Hospital Heidelberg, Heidelberg, Germany

Phase III randomised trial comparing tebentafusp with investigator’s choice in first-line metastatic uveal melanoma ( Dr Jessica Hassel - University Hospital Heidelberg, Heidelberg, Germany )

Adjuvant therapy with nivolumab combined with ipilimumab vs nivolumab alone in...

Prof Georgina Long - University of Sydney, Sydney, Australia

Adjuvant therapy with nivolumab combined with ipilimumab vs nivolumab alone in patients with resected stage IIIB-D/IV melanoma ( Prof Georgina Long - University of Sydney, Sydney, Australia )

Autologous tumour infiltrating lymphocytes cell therapy in metastatic non-small...

Dr Erminia Massarelli - City of Hope, Duarte, USA

Autologous tumour infiltrating lymphocytes cell therapy in metastatic non-small cell lung cancer ( Dr Erminia Massarelli - City of Hope, Duarte, USA )

OncoAlert and ecancer weekly roundup for January 25 - 31, 2021

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer weekly roundup for January 25 - 31, 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

Advances and challenges in treating melanoma and breast cancer in Romania

Dr Daniela Zob - Institute of Oncology, Bucharest, Romania

Advances and challenges in treating melanoma and breast cancer in Romania ( Dr Daniela Zob - Institute of Oncology, Bucharest, Romania )

OncoAlert Colloquium Day 4: Gynae-oncology, lymphoma, sarcoma and melanoma

Dr Dizon, Dr Trent, Dr Cordoba, Dr Rolfo, Dr Haanen

OncoAlert Colloquium Day 4: Gynae-oncology, lymphoma, sarcoma and melanoma ( Dr Dizon, Dr Trent, Dr Cordoba, Dr Rolfo, Dr Haanen )

More from ecancer